Midatech has announced it has entered into a research collaboration with Dr Reddy’s Laboratories (BSE:500124, NSE:DRREDDY, NYSE:RDY) (‘Dr. Reddy’s), the global pharmaceutical company.
One (or possibly more) of the Group’s proprietary technology platforms, each with their own unique mechanism focused on improving bio-delivery and biodistribution, is/are to be applied together with its in-house expertise, to certain of Dr Reddy’s nominated existing medicines with a view to expanding their treatment options.
Such an endorsement ideally reflects the value and unique qualities of Midatech’s technologies for drug development beyond that of its own internal pipeline.
The scale of Dr Reddy’s portfolio of products and services, that stretch across multiple therapeutic areas and reach global consumers, now presents a potentially giant, reputation-building opportunity for the Group from which it could accrue a stream of long-term licence fees, followed by milestone payments and royalties upon successful commercialisation of any co-developed product(s).
We would draw your attention to the various disclaimers in the document both at the beginning and at the end of the note. Retail clients (as defined by the rules of the FCA) must not rely on the research document. In particular you should note that the research document is a non-independent marketing communication. The analyst who has prepared the research is aware that TPI provides research to Midatech Pharma plc. Accordingly the research has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibitions on dealing ahead of its dissemination.
The information in the document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.
Copyright © 2020 Turner Pope Investments (TPI) Limited, all rights reserved.
If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.
Terms of Website Use
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned